Cingulate Inc. (CING): Nasdaq/NYSE listing notice — Cingulate receives Nasdaq delisting notice for continued non-compliance with equity rule; intends to request hearing

Cingulate Inc.

Nasdaq staff determined to delist CING common stock and warrants unless a hearing is timely requested.
Company failed to regain compliance with $2.5M minimum stockholders' equity by Nov 13, 2023 deadline.
Company intends to request a hearing before Nasdaq Hearings Panel to seek an extension.
Also noted separate bid price deficiency; compliance period extends to Jan 24, 2024.
If delisted, liquidity and capital access could be materially adversely affected.

item 3.01 item 8.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Cingulate Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

November 14, 2023, Cingulate Inc. (the “Company”) received a letter from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the Company’s continued non-compliance with the minimum stockholders’ equity requirement in Listing Rule 5550(b)(1) (the “Minimum Stockholders’ Equity Rule”) for continued listing on The Nasdaq Capital Market, the Staff had determined to delist the Company’s securities from Nasdaq unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the “Panel”). The Company intends to timely reque

View on SEC.gov

Browse all listing & compliance notices →

Cingulate Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-041199

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.